Company Name | Bayer Taiwan Co., Ltd |
---|---|
Protocol Number | 21960 |
Title of Study | Copanlisib in Indolent Non-Hodgkin Lymphoma Patients: A Real-world Taiwan Observation Multicenter Study |
Primary Objective | To describe the real-world utilization of copanlisib for the treatment of relapse/refractory iNHL in Taiwan |
Number of Sites | 4 |
Period of Study | From:2022 Q2 to:2024 Q4 |
Number of Patients | 50人 |
IRB Approval Date | NTUH 2022/04/25 KFSYSCC 2022/05/28 CYCH In Progress KHCGMH In preparation |
Publication Plan / Date | Unknown |